

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SLAYBACK PHARMA LLC,

Petitioner,

v.

EYE THERAPIES, LLC,

Patent Owner.

Case IPR2022-00142
U.S. Patent No. 8,293,742

DECLARATION OF STEPHEN G. DAVIES, D.PHIL.

Table of Contents

I.	QUALIFICATIONS AND BACKGROUND.....	1
A.	Education and Experience.....	1
B.	Documents and Information Considered in Forming Opinions.....	4
C.	Scope of Work, Compensation.....	4
D.	Testimony as Expert in Last Four Years.....	5
II.	LEGAL STANDARDS	5
III.	STATEMENTS OF OPINIONS EXPRESSED AND BASES AND REASONS THEREFOR	6
A.	U.S. Patent No. 8,293,742	6
B.	A Person of Ordinary Skill in the Art	7
C.	Claim Construction.....	9
D.	Technical Tutorial	10
1.	Different Chemical Compounds Have Different Characteristics.....	10
2.	Chemistry of Brimonidine	11
3.	Chemistry of Naphazoline and Tetrahydrozoline.....	13
4.	Three Dimensional Structures of Brimonidine, Naphazoline, and Tetrahydrozoline.....	14
5.	Additional Selected Compounds	16
E.	Response to Dr. Laskar’s Section Entitled “2-Imidazoline Derivatives Were Known as Vasoconstrictors for Reducing Eye Redness”	18

I. QUALIFICATIONS AND BACKGROUND

A. Education and Experience

1. I, Stephen G. Davies, D.Phil., submit this declaration at the request of Eye Therapies, LLC (“Eye Therapies” or “Patent Owner”) as an expert in the fields of organic chemistry and medicinal chemistry. I understand this is being submitted in support of the Patent Owner’s Response in connection with IPR2022-00142. My qualifications in these areas, as well as other areas, are established below and by my curriculum vitae, which is attached as Appendix A, and list of publications, which is attached as Appendix B.

2. I am the Waynflete Professor of Chemistry Emeritus at the University of Oxford, and Extraordinary Lecturer in Chemistry at New College, Oxford, England. I have been employed teaching chemistry at Oxford since 1980. From 2006 to 2011, I was Chairman of the Department of Chemistry. In this position, I had full responsibility for all teaching, research, financial and managerial matters in one of the largest chemistry departments in the world. I have also supervised more than 100 graduate students and 100 post-doctoral fellows in the areas of organic, organometallic and medicinal chemistry.

3. In 1973, I earned a B.A. in Chemistry from the University of Oxford. In 1975, I earned a D. Phil. in Chemistry from the University of Oxford. In 1980, I received a D. Sc. in Chemistry from the University of Paris.

4. Over the course of my career, I have been a committee member of many professional organizations, a list of which can be found in my *curriculum vitae*.

5. I have authored over 600 publications and have given scores of research lectures. My research interests include synthetic organic and medicinal chemistry, and in particular, the preparation of chemically and stereochemically pure organic compounds, including the asymmetric and stereoselective synthesis of enantiomerically pure organic compounds for potential therapeutic use. A list of my publications may be found attached as Appendix B.

6. I have also held several editorial appointments. I was the Founding Editor and Editor of Organic Series of “Oxford Chemistry Primers” and “Oxford Chemistry Masters.” I was also the Founding Editor and currently Editor-in-chief of “Tetrahedron: Asymmetry” (1990-2017). I am also the Editor of the “On Chemistry” Books, and for many years (1989-2017), I was an Executive Editorial Board Member of the “Tetrahedron” family of Journals.

7. Over the course of my career, I have received several awards, including the Hickinbottom Fellowship (1984); Pfizer Award for Chemistry (1985); 1984 Corday Morgan Medal, Royal Society of Chemistry (1986); Royal Society of Chemistry Award for Organometallic Chemistry (1987); Pfizer Award for Chemistry (1988); Royal Society of Chemistry Bader Award (1989); Tilden Lecture Award, Royal Society of Chemistry (1996); Royal Society of Chemistry Award in

Stereochemistry (1997); Prize Lectureship of the Society of Synthetic Organic Chemistry, Japan (1998); Distinguished Technopreneur Award, Singapore (2008); Royal Society of Chemistry Perkin Prize for Organic Chemistry (2011); and Doctor Honoris Causa, University of Salamanca, Spain.

8. I am also the founder of numerous companies including ones focused on the preparation of compounds for potential pharmaceutical use. Along with several others, I founded Oxford Asymmetry, Ltd. in 1992, which became a division of Oxford Asymmetry International plc, with a mission to provide pharmaceutical companies with enantiomerically pure compounds of interest on any desired scale, from small amounts for biological evaluation and research, to commercial quantities. Currently, I am the Founder and Non-executive Chairman of SciInk Ltd. I was also a Non-executive Director of Oxford University Innovation Ltd. I was also the Founder and Non-executive Director of OxStem Ltd., OxStem Neuro Ltd., OxStem Cardio Ltd., OxStem Oncology Ltd., OxStem Ocular Ltd, OxStem Beta Ltd, and OxStem Immuno Ltd. I am also the Founder of Summit Therapeutics plc and Summit Therapeutics Inc., which develops pharmaceutical compounds and has one such compound currently undergoing evaluation after a Phase III clinical trial. I am also the Founder and Non-executive Director of Raphael Laboratories Limited, which is developing prophylactics against airborne respiratory viruses

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.